Netakimab

Phase 3Monoclonal antibody

SSPH-BIOCAD (HK) Limited

Netakimab is one of 82 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

PsoriasisActive, not recruiting

COVID-19Preclinical

Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Netakimab

SSPH-BIOCAD (HK) Limited

Phase 3

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Statin

Bristol-Myers Squibb

Preclinical

1 8

Glucocorticoid

AbbVie

Preclinical

1 9

Statins

Sanofi

Preclinical

1 10

Rayaldee

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Psoriasis

NCT06640517

Clinical

Trials by Indication[1]

Psoriasis1 trial

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Active, not recruiting·BBiocad·Phase 3·NCT06640517·140 enrolled

COVID-191 trial

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed·PPirogov Russian National Research Medical University··NCT05302947·154 enrolled

Ankylosing Spondylitis1 trial

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

Completed·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07277179·113 enrolled

Plaque Psoriasis1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Moderate to Severe Plaque Psoriasis

Completed·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07008547·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Netakimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netakimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netakimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SPH-BIOCAD (HK) Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SSPH-BIOCAD (HK) Limited

Netakimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Psoriasis1 trial

COVID-191 trial

Ankylosing Spondylitis1 trial

Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News